Enteric coated multiparticulate controlled release peppermint oil composition and related methods
A multiparticulate composition is formed from a plurality of individual cores including a hydrophobic phase containing peppermint oil dispersed in a microcrystalline cellulose-based gel and a hydrophilic phase containing a hydrogel. An enteric coating is over the individual cores. The multiparticulate composition can be used to treat gastrointestinal disorders.
1. A composition providing controlled-release of peppermint oil, the composition comprising a plurality of enteric coated solid spheroidal cores, the cores comprising peppermint oil, microcrystalline cellulose, and a hydrophilic binder, the cores having a diameter of about 0.1 to about 3 mm.
2. The composition of claim 1 , wherein the cores are spheroidal and have a diameter of about 1 mm to about 2.5 mm.
3. The composition of claim 1 , wherein the cores are spheroidal and have a diameter of less than about 1.4 mm.
4. The composition of claim 1 , wherein the cores release no more than about 20% of the peppermint oil within about two hours of being placed in a 0.1 N HCl solution and, subsequently no less than about 85% of the peppermint oil within about eight hours of being placed in a substantially neutral pH environment.
5. The composition of claim 1 , wherein the cores release no more than about 20% of the peppermint oil within about two hours of being placed in a 0.1 N HCl solution and, subsequently no less than about 60% of the peppermint oil within about two hours of being placed in a substantially neutral pH environment.
6. The composition of claim 1 , wherein the peppermint oil in the cores is present in combination with at least one terpene-based substance selected from L-menthol, caraway oil, orange oil, ginger oil, turmeric oil, curcumin, and fennel oil.
7. The composition of claim 1 , wherein the peppermint oil in the cores includes L-menthol and the peppermint oil is present in combination with more L-menthol than provided by the peppermint oil itself.
8. The composition of claim 1 , wherein the peppermint oil in the cores is present in combination with caraway oil.
9. The composition of claim 1 , wherein the cores further comprise a continuous proteinaceous subcoating layer positioned between the solid core and enteric coating.
10. The composition of claim 9 , wherein the proteinaceous subcoating layer comprises a gelatin film adhered to the solid core.
11. The composition of claim 9 , wherein the proteinaceous subcoating layer comprises a dried proteinaceous gel.
12. The composition of claim 1 , wherein the hydrophilic binder is methylcellulose.
13. The composition of claim 1 , wherein the hydrophilic binder is selected from starch-based, cellulose-based, and povidone-based materials.
14. The composition of claim 1 , wherein the cores comprise about 15% w/w to about 40% w/w peppermint oil, about 35% w/w to about 75% w/w microcrystalline cellulose, and about 2% w/w to about 15% w/w methylcellulose.
15. The composition of claim 1 , wherein the enteric coating comprises a methacrylic acid-based co-polymer.
16. The composition of claim 1 , wherein the cores further comprise at least one disintegrant selected from croscarmellose sodium, polyvinylpyrrolidone, and sodium starch glycolate.
17. An oral controlled-release multiparticulate dosage form comprising a plurality of individually enteric coated peppermint oil containing particulates that independently disperse in a subject's stomach after oral ingestion and travel through the stomach without substantially releasing the peppermint oil therein, the individual particulates comprising (a) a solid core containing peppermint oil, microcrystalline cellulose, and a hydrophilic binder; and (b) an enteric coat over the core.
18. The dosage form of claim 17 , wherein the individual particulates are spheroidal and have a diameter of about 0.1 mm to about 3 mm.
19. The dosage form of claim 18 , wherein the diameter is about 1 mm to about 2.5 mm.
20. The dosage form of claim 18 , wherein the diameter is about 1 mm to about 1.4 mm.
21. The dosage form of claim 17 , wherein the individual particulates release no more than about 20% of the peppermint oil within about two hours of being placed in a 0.1 N HCl solution and, subsequently no less than about 85% of the peppermint oil within about eight hours of being placed in a substantially neutral pH environment.
22. The dosage form of claim 17 , wherein the individual particulates release no more than about 20% of the peppermint oil within about two hours of being placed in a 0.1 N HCl solution and, subsequently no less than about 60% of the peppermint oil within about two hours of being placed in a substantially neutral pH environment.
23. The dosage form of claim 17 , wherein the peppermint oil in the individual particulates is present in combination with at least one terpene-based substance selected from L-menthol, caraway oil, orange oil, ginger oil, turmeric oil, curcumin, and fennel oil.
24. The dosage form of claim 17 , wherein the peppermint oil in the individual particulates includes L-menthol and the peppermint oil is present in combination with more L-menthol than provided by the peppermint oil itself.
25. The dosage form of claim 17 , wherein the peppermint oil in the individual particulates is present in combination with caraway oil.
26. The dosage form of claim 17 , wherein the individual particulates further comprise a continuous proteinaceous subcoating layer positioned between the core and enteric coating.
27. The dosage form of claim 26 , wherein the proteinaceous subcoating layer comprises a gelatin film adhered to the solid core.
28. The dosage form of claim 26 , wherein the proteinaceous subcoating layer comprises a dried proteinaceous gel.
29. The dosage form of claim 17 , wherein the hydrophilic binder is methylcellulose.
30. The dosage form of claim 17 , wherein the hydrophilic binder is selected from starch-based, cellulose-based, and povidone-based materials.
31. The dosage form of claim 17 , wherein the cores comprise about 15% w/w to about 40% w/w peppermint oil, about 35% w/w to about 75% w/w microcrystalline cellulose, and about 2% w/w to about 15% w/w methylcellulose.
32. The dosage form of claim 17 , wherein the enteric coating comprises a methacrylic acid-based co-polymer.
33. The dosage form of claim 17 , wherein the cores further comprise at least one disintegrant selected from croscarmellose sodium, polyvinylpyrrolidone, and sodium starch glycolate.